Effect of Subcutaneous Unfractionated Heparin Prophylaxis on Activated Partial Thromboplastin Time: A Retrospective Evaluation

Abstract Study Objective Characterize the incidence of elevated aPTT results in patients treated with prophylactic, subcutaneous unfractionated heparin (UFH). Design Retrospective, cohort analysis. Setting Single-center, university hospital. Measurements Evaluation of 257 patients with activated par...

Full description

Saved in:
Bibliographic Details
Published in:Journal of clinical anesthesia 2016-09, Vol.33, p.346-350
Main Authors: Thompson, Molly H., PharmD, BCPS, Wilson, Sylvia H., MD, Toussaint, Brittany L., PharmD, BCPS, Jordan, Cameron L., PharmD, BCPS, Hayes, Genevieve L., PharmD, MSPharm, BCPS, McKinzie, Brian P., PharmD, BCPS, BCNSP, Wolf, Bethany J., Ph.D, Field, Larry C., MD
Format: Article
Language:English
Subjects:
Activated partial thromboplastin time
Adult
Age
Age Factors
Aged
Anesthesia & Perioperative Care
Anticoagulants
Anticoagulants - adverse effects
Anticoagulants - therapeutic use
Blood products
Blood Transfusion
Body mass index
Cohort Studies
Ethnic Groups
Female
Heparin - adverse effects
Heparin - therapeutic use
Humans
Injections, Subcutaneous
Intraoperative Complications - prevention & control
Laboratories
Liver Diseases - blood
Male
Middle Aged
Multivariate analysis
Pain Medicine
Partial Thromboplastin Time
Patients
Retrospective Studies
Sex Characteristics
Thoracic surgery
Unfractionated heparin
Venous Thromboembolism - prevention & control
Venous thromboembolism prophylaxis
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c587t-c56e23e5ad52cfb439596eb9d08798ed9616a45c83dc190de1e42e11729da5e53
cites cdi_FETCH-LOGICAL-c587t-c56e23e5ad52cfb439596eb9d08798ed9616a45c83dc190de1e42e11729da5e53
container_end_page 350
container_issue
container_start_page 346
container_title Journal of clinical anesthesia
container_volume 33
creator Thompson, Molly H., PharmD, BCPS
Wilson, Sylvia H., MD
Toussaint, Brittany L., PharmD, BCPS
Jordan, Cameron L., PharmD, BCPS
Hayes, Genevieve L., PharmD, MSPharm, BCPS
McKinzie, Brian P., PharmD, BCPS, BCNSP
Wolf, Bethany J., Ph.D
Field, Larry C., MD
description Abstract Study Objective Characterize the incidence of elevated aPTT results in patients treated with prophylactic, subcutaneous unfractionated heparin (UFH). Design Retrospective, cohort analysis. Setting Single-center, university hospital. Measurements Evaluation of 257 patients with activated partial thromboplastin time (aPTT) testing both prior to and following subcutaneous (SC) unfractionated heparin (UFH) therapy. Main Results Evaluated patients received UFH 5000 units every 8 hours. Baseline aPTT values were within the normal range (mean ± SD, 32.0 ± 8.5 seconds). After initiation of UFH, aPTT values increased (mean ± SD, 37.6 ± 15.2 seconds). After 24 hours of SC UFH, mean aPTT values (mean ± SD, 38.6 ± 15.5) exceeded the normal laboratory range (23.3–35.7 seconds). An elevated aPTT result after UFH was associated with baseline aPTT, length of therapy, and weight-based UFH dose. A significant association was not identified between aPTT elevation and age, race, sex, history of liver disease, type of admission, or transfusion of blood products. Conclusions Treatment with UFH resulted in a small, but significant, increase in aPTT.
doi_str_mv 10.1016/j.jclinane.2015.11.020
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5784767</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0952818016301349</els_id><sourcerecordid>4225217071</sourcerecordid><originalsourceid>FETCH-LOGICAL-c587t-c56e23e5ad52cfb439596eb9d08798ed9616a45c83dc190de1e42e11729da5e53</originalsourceid><addsrcrecordid>eNqNksFu1DAQhiMEotvCK1SWuHDZxWPHScyhYlUtFKkSFd2eLa8zYR2SONjJqnvh2euwbYFeQJbsw3zzj2fmT5JToAugkL2rF7VpbKc7XDAKYgGwoIw-S2ZQ5HyeCiafJzMqBZsXUNCj5DiEmlIaA_AyOWK5EAIkzJKfq6pCMxBXketxY8YhKroxkJuu8toM1nV6wJJcYK-97ciVd_123-hbG4jryDISu1_AlfaD1Q1Zb71rN65vdBgiv7YtvidL8hUH70KPE49ktdPNqCfxV8mLSjcBX9-_J8nNx9X6_GJ--eXT5_Pl5dyIIh_inSHjKHQpmKk2KZdCZriRJS1yWWApM8h0KkzBSwOSlgiYMgTImSy1QMFPkrODbj9uWiwNdoPXjeq9bbXfK6et-jvS2a365nZK5EWaZ3kUeHsv4N2PEcOgWhsMNs1hXgoKHotlBc_-A4U0HiYm1TdP0NqNvouTmASBM5bnMlLZgTJxhsFj9fhvoGpyg6rVgxvU5AYFoKIbYuLpn10_pj2sPwIfDgDG2e8sehWMxc5gaX3clSqd_XeNsycSE2WNbr7jHsPvflRgiqrryZOTJSHjFHgq-R3WQODP</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1831322779</pqid></control><display><type>article</type><title>Effect of Subcutaneous Unfractionated Heparin Prophylaxis on Activated Partial Thromboplastin Time: A Retrospective Evaluation</title><source>ScienceDirect Freedom Collection</source><creator>Thompson, Molly H., PharmD, BCPS ; Wilson, Sylvia H., MD ; Toussaint, Brittany L., PharmD, BCPS ; Jordan, Cameron L., PharmD, BCPS ; Hayes, Genevieve L., PharmD, MSPharm, BCPS ; McKinzie, Brian P., PharmD, BCPS, BCNSP ; Wolf, Bethany J., Ph.D ; Field, Larry C., MD</creator><creatorcontrib>Thompson, Molly H., PharmD, BCPS ; Wilson, Sylvia H., MD ; Toussaint, Brittany L., PharmD, BCPS ; Jordan, Cameron L., PharmD, BCPS ; Hayes, Genevieve L., PharmD, MSPharm, BCPS ; McKinzie, Brian P., PharmD, BCPS, BCNSP ; Wolf, Bethany J., Ph.D ; Field, Larry C., MD</creatorcontrib><description>Abstract Study Objective Characterize the incidence of elevated aPTT results in patients treated with prophylactic, subcutaneous unfractionated heparin (UFH). Design Retrospective, cohort analysis. Setting Single-center, university hospital. Measurements Evaluation of 257 patients with activated partial thromboplastin time (aPTT) testing both prior to and following subcutaneous (SC) unfractionated heparin (UFH) therapy. Main Results Evaluated patients received UFH 5000 units every 8 hours. Baseline aPTT values were within the normal range (mean ± SD, 32.0 ± 8.5 seconds). After initiation of UFH, aPTT values increased (mean ± SD, 37.6 ± 15.2 seconds). After 24 hours of SC UFH, mean aPTT values (mean ± SD, 38.6 ± 15.5) exceeded the normal laboratory range (23.3–35.7 seconds). An elevated aPTT result after UFH was associated with baseline aPTT, length of therapy, and weight-based UFH dose. A significant association was not identified between aPTT elevation and age, race, sex, history of liver disease, type of admission, or transfusion of blood products. Conclusions Treatment with UFH resulted in a small, but significant, increase in aPTT.</description><identifier>ISSN: 0952-8180</identifier><identifier>EISSN: 1873-4529</identifier><identifier>DOI: 10.1016/j.jclinane.2015.11.020</identifier><identifier>PMID: 27555191</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Activated partial thromboplastin time ; Adult ; Age ; Age Factors ; Aged ; Anesthesia &amp; Perioperative Care ; Anticoagulants ; Anticoagulants - adverse effects ; Anticoagulants - therapeutic use ; Blood products ; Blood Transfusion ; Body mass index ; Cohort Studies ; Ethnic Groups ; Female ; Heparin - adverse effects ; Heparin - therapeutic use ; Humans ; Injections, Subcutaneous ; Intraoperative Complications - prevention &amp; control ; Laboratories ; Liver Diseases - blood ; Male ; Middle Aged ; Multivariate analysis ; Pain Medicine ; Partial Thromboplastin Time ; Patients ; Retrospective Studies ; Sex Characteristics ; Thoracic surgery ; Unfractionated heparin ; Venous Thromboembolism - prevention &amp; control ; Venous thromboembolism prophylaxis</subject><ispartof>Journal of clinical anesthesia, 2016-09, Vol.33, p.346-350</ispartof><rights>Elsevier Inc.</rights><rights>2016 Elsevier Inc.</rights><rights>Copyright © 2016 Elsevier Inc. All rights reserved.</rights><rights>Copyright Elsevier Limited Sep 2016</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c587t-c56e23e5ad52cfb439596eb9d08798ed9616a45c83dc190de1e42e11729da5e53</citedby><cites>FETCH-LOGICAL-c587t-c56e23e5ad52cfb439596eb9d08798ed9616a45c83dc190de1e42e11729da5e53</cites><orcidid>0000-0002-5259-7879 ; 0000-0003-1401-5628 ; 0000-0003-0524-2503 ; 0000-0002-8975-5375</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,315,786,790,891,27957,27958</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27555191$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Thompson, Molly H., PharmD, BCPS</creatorcontrib><creatorcontrib>Wilson, Sylvia H., MD</creatorcontrib><creatorcontrib>Toussaint, Brittany L., PharmD, BCPS</creatorcontrib><creatorcontrib>Jordan, Cameron L., PharmD, BCPS</creatorcontrib><creatorcontrib>Hayes, Genevieve L., PharmD, MSPharm, BCPS</creatorcontrib><creatorcontrib>McKinzie, Brian P., PharmD, BCPS, BCNSP</creatorcontrib><creatorcontrib>Wolf, Bethany J., Ph.D</creatorcontrib><creatorcontrib>Field, Larry C., MD</creatorcontrib><title>Effect of Subcutaneous Unfractionated Heparin Prophylaxis on Activated Partial Thromboplastin Time: A Retrospective Evaluation</title><title>Journal of clinical anesthesia</title><addtitle>J Clin Anesth</addtitle><description>Abstract Study Objective Characterize the incidence of elevated aPTT results in patients treated with prophylactic, subcutaneous unfractionated heparin (UFH). Design Retrospective, cohort analysis. Setting Single-center, university hospital. Measurements Evaluation of 257 patients with activated partial thromboplastin time (aPTT) testing both prior to and following subcutaneous (SC) unfractionated heparin (UFH) therapy. Main Results Evaluated patients received UFH 5000 units every 8 hours. Baseline aPTT values were within the normal range (mean ± SD, 32.0 ± 8.5 seconds). After initiation of UFH, aPTT values increased (mean ± SD, 37.6 ± 15.2 seconds). After 24 hours of SC UFH, mean aPTT values (mean ± SD, 38.6 ± 15.5) exceeded the normal laboratory range (23.3–35.7 seconds). An elevated aPTT result after UFH was associated with baseline aPTT, length of therapy, and weight-based UFH dose. A significant association was not identified between aPTT elevation and age, race, sex, history of liver disease, type of admission, or transfusion of blood products. Conclusions Treatment with UFH resulted in a small, but significant, increase in aPTT.</description><subject>Activated partial thromboplastin time</subject><subject>Adult</subject><subject>Age</subject><subject>Age Factors</subject><subject>Aged</subject><subject>Anesthesia &amp; Perioperative Care</subject><subject>Anticoagulants</subject><subject>Anticoagulants - adverse effects</subject><subject>Anticoagulants - therapeutic use</subject><subject>Blood products</subject><subject>Blood Transfusion</subject><subject>Body mass index</subject><subject>Cohort Studies</subject><subject>Ethnic Groups</subject><subject>Female</subject><subject>Heparin - adverse effects</subject><subject>Heparin - therapeutic use</subject><subject>Humans</subject><subject>Injections, Subcutaneous</subject><subject>Intraoperative Complications - prevention &amp; control</subject><subject>Laboratories</subject><subject>Liver Diseases - blood</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Multivariate analysis</subject><subject>Pain Medicine</subject><subject>Partial Thromboplastin Time</subject><subject>Patients</subject><subject>Retrospective Studies</subject><subject>Sex Characteristics</subject><subject>Thoracic surgery</subject><subject>Unfractionated heparin</subject><subject>Venous Thromboembolism - prevention &amp; control</subject><subject>Venous thromboembolism prophylaxis</subject><issn>0952-8180</issn><issn>1873-4529</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><recordid>eNqNksFu1DAQhiMEotvCK1SWuHDZxWPHScyhYlUtFKkSFd2eLa8zYR2SONjJqnvh2euwbYFeQJbsw3zzj2fmT5JToAugkL2rF7VpbKc7XDAKYgGwoIw-S2ZQ5HyeCiafJzMqBZsXUNCj5DiEmlIaA_AyOWK5EAIkzJKfq6pCMxBXketxY8YhKroxkJuu8toM1nV6wJJcYK-97ciVd_123-hbG4jryDISu1_AlfaD1Q1Zb71rN65vdBgiv7YtvidL8hUH70KPE49ktdPNqCfxV8mLSjcBX9-_J8nNx9X6_GJ--eXT5_Pl5dyIIh_inSHjKHQpmKk2KZdCZriRJS1yWWApM8h0KkzBSwOSlgiYMgTImSy1QMFPkrODbj9uWiwNdoPXjeq9bbXfK6et-jvS2a365nZK5EWaZ3kUeHsv4N2PEcOgWhsMNs1hXgoKHotlBc_-A4U0HiYm1TdP0NqNvouTmASBM5bnMlLZgTJxhsFj9fhvoGpyg6rVgxvU5AYFoKIbYuLpn10_pj2sPwIfDgDG2e8sehWMxc5gaX3clSqd_XeNsycSE2WNbr7jHsPvflRgiqrryZOTJSHjFHgq-R3WQODP</recordid><startdate>20160901</startdate><enddate>20160901</enddate><creator>Thompson, Molly H., PharmD, BCPS</creator><creator>Wilson, Sylvia H., MD</creator><creator>Toussaint, Brittany L., PharmD, BCPS</creator><creator>Jordan, Cameron L., PharmD, BCPS</creator><creator>Hayes, Genevieve L., PharmD, MSPharm, BCPS</creator><creator>McKinzie, Brian P., PharmD, BCPS, BCNSP</creator><creator>Wolf, Bethany J., Ph.D</creator><creator>Field, Larry C., MD</creator><general>Elsevier Inc</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>7QO</scope><scope>7U7</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>P64</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-5259-7879</orcidid><orcidid>https://orcid.org/0000-0003-1401-5628</orcidid><orcidid>https://orcid.org/0000-0003-0524-2503</orcidid><orcidid>https://orcid.org/0000-0002-8975-5375</orcidid></search><sort><creationdate>20160901</creationdate><title>Effect of Subcutaneous Unfractionated Heparin Prophylaxis on Activated Partial Thromboplastin Time: A Retrospective Evaluation</title><author>Thompson, Molly H., PharmD, BCPS ; Wilson, Sylvia H., MD ; Toussaint, Brittany L., PharmD, BCPS ; Jordan, Cameron L., PharmD, BCPS ; Hayes, Genevieve L., PharmD, MSPharm, BCPS ; McKinzie, Brian P., PharmD, BCPS, BCNSP ; Wolf, Bethany J., Ph.D ; Field, Larry C., MD</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c587t-c56e23e5ad52cfb439596eb9d08798ed9616a45c83dc190de1e42e11729da5e53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Activated partial thromboplastin time</topic><topic>Adult</topic><topic>Age</topic><topic>Age Factors</topic><topic>Aged</topic><topic>Anesthesia &amp; Perioperative Care</topic><topic>Anticoagulants</topic><topic>Anticoagulants - adverse effects</topic><topic>Anticoagulants - therapeutic use</topic><topic>Blood products</topic><topic>Blood Transfusion</topic><topic>Body mass index</topic><topic>Cohort Studies</topic><topic>Ethnic Groups</topic><topic>Female</topic><topic>Heparin - adverse effects</topic><topic>Heparin - therapeutic use</topic><topic>Humans</topic><topic>Injections, Subcutaneous</topic><topic>Intraoperative Complications - prevention &amp; control</topic><topic>Laboratories</topic><topic>Liver Diseases - blood</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Multivariate analysis</topic><topic>Pain Medicine</topic><topic>Partial Thromboplastin Time</topic><topic>Patients</topic><topic>Retrospective Studies</topic><topic>Sex Characteristics</topic><topic>Thoracic surgery</topic><topic>Unfractionated heparin</topic><topic>Venous Thromboembolism - prevention &amp; control</topic><topic>Venous thromboembolism prophylaxis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Thompson, Molly H., PharmD, BCPS</creatorcontrib><creatorcontrib>Wilson, Sylvia H., MD</creatorcontrib><creatorcontrib>Toussaint, Brittany L., PharmD, BCPS</creatorcontrib><creatorcontrib>Jordan, Cameron L., PharmD, BCPS</creatorcontrib><creatorcontrib>Hayes, Genevieve L., PharmD, MSPharm, BCPS</creatorcontrib><creatorcontrib>McKinzie, Brian P., PharmD, BCPS, BCNSP</creatorcontrib><creatorcontrib>Wolf, Bethany J., Ph.D</creatorcontrib><creatorcontrib>Field, Larry C., MD</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Nursing &amp; Allied Health Database</collection><collection>ProQuest Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>ProQuest research library</collection><collection>Research Library (Corporate)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>Biotechnology Research Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of clinical anesthesia</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Thompson, Molly H., PharmD, BCPS</au><au>Wilson, Sylvia H., MD</au><au>Toussaint, Brittany L., PharmD, BCPS</au><au>Jordan, Cameron L., PharmD, BCPS</au><au>Hayes, Genevieve L., PharmD, MSPharm, BCPS</au><au>McKinzie, Brian P., PharmD, BCPS, BCNSP</au><au>Wolf, Bethany J., Ph.D</au><au>Field, Larry C., MD</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effect of Subcutaneous Unfractionated Heparin Prophylaxis on Activated Partial Thromboplastin Time: A Retrospective Evaluation</atitle><jtitle>Journal of clinical anesthesia</jtitle><addtitle>J Clin Anesth</addtitle><date>2016-09-01</date><risdate>2016</risdate><volume>33</volume><spage>346</spage><epage>350</epage><pages>346-350</pages><issn>0952-8180</issn><eissn>1873-4529</eissn><notes>ObjectType-Article-1</notes><notes>SourceType-Scholarly Journals-1</notes><notes>ObjectType-Feature-2</notes><notes>content type line 23</notes><notes>At the time of writing</notes><abstract>Abstract Study Objective Characterize the incidence of elevated aPTT results in patients treated with prophylactic, subcutaneous unfractionated heparin (UFH). Design Retrospective, cohort analysis. Setting Single-center, university hospital. Measurements Evaluation of 257 patients with activated partial thromboplastin time (aPTT) testing both prior to and following subcutaneous (SC) unfractionated heparin (UFH) therapy. Main Results Evaluated patients received UFH 5000 units every 8 hours. Baseline aPTT values were within the normal range (mean ± SD, 32.0 ± 8.5 seconds). After initiation of UFH, aPTT values increased (mean ± SD, 37.6 ± 15.2 seconds). After 24 hours of SC UFH, mean aPTT values (mean ± SD, 38.6 ± 15.5) exceeded the normal laboratory range (23.3–35.7 seconds). An elevated aPTT result after UFH was associated with baseline aPTT, length of therapy, and weight-based UFH dose. A significant association was not identified between aPTT elevation and age, race, sex, history of liver disease, type of admission, or transfusion of blood products. Conclusions Treatment with UFH resulted in a small, but significant, increase in aPTT.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>27555191</pmid><doi>10.1016/j.jclinane.2015.11.020</doi><tpages>5</tpages><orcidid>https://orcid.org/0000-0002-5259-7879</orcidid><orcidid>https://orcid.org/0000-0003-1401-5628</orcidid><orcidid>https://orcid.org/0000-0003-0524-2503</orcidid><orcidid>https://orcid.org/0000-0002-8975-5375</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0952-8180
ispartof Journal of clinical anesthesia, 2016-09, Vol.33, p.346-350
issn 0952-8180
1873-4529
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5784767
source ScienceDirect Freedom Collection
subjects Activated partial thromboplastin time
Adult
Age
Age Factors
Aged
Anesthesia & Perioperative Care
Anticoagulants
Anticoagulants - adverse effects
Anticoagulants - therapeutic use
Blood products
Blood Transfusion
Body mass index
Cohort Studies
Ethnic Groups
Female
Heparin - adverse effects
Heparin - therapeutic use
Humans
Injections, Subcutaneous
Intraoperative Complications - prevention & control
Laboratories
Liver Diseases - blood
Male
Middle Aged
Multivariate analysis
Pain Medicine
Partial Thromboplastin Time
Patients
Retrospective Studies
Sex Characteristics
Thoracic surgery
Unfractionated heparin
Venous Thromboembolism - prevention & control
Venous thromboembolism prophylaxis
title Effect of Subcutaneous Unfractionated Heparin Prophylaxis on Activated Partial Thromboplastin Time: A Retrospective Evaluation
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-09-22T15%3A20%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effect%20of%20Subcutaneous%20Unfractionated%20Heparin%20Prophylaxis%20on%20Activated%20Partial%20Thromboplastin%20Time:%20A%20Retrospective%20Evaluation&rft.jtitle=Journal%20of%20clinical%20anesthesia&rft.au=Thompson,%20Molly%20H.,%20PharmD,%20BCPS&rft.date=2016-09-01&rft.volume=33&rft.spage=346&rft.epage=350&rft.pages=346-350&rft.issn=0952-8180&rft.eissn=1873-4529&rft_id=info:doi/10.1016/j.jclinane.2015.11.020&rft_dat=%3Cproquest_pubme%3E4225217071%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c587t-c56e23e5ad52cfb439596eb9d08798ed9616a45c83dc190de1e42e11729da5e53%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1831322779&rft_id=info:pmid/27555191&rfr_iscdi=true